Dr. Wang Discusses Acalabrutinib in MCL

Michael Wang, MD
Published: Thursday, Dec 21, 2017



Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).

Acalabrutinib is a second-generation BTK inhibitor that was recently approved by the FDA for the treatment of adult patients with MCL following at least 1 prior therapy.

Wang says that targeted therapies should not be underestimated in this disease, as they are a very powerful alternative to chemotherapy.

SELECTED
LANGUAGE


Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma (MCL).

Acalabrutinib is a second-generation BTK inhibitor that was recently approved by the FDA for the treatment of adult patients with MCL following at least 1 prior therapy.

Wang says that targeted therapies should not be underestimated in this disease, as they are a very powerful alternative to chemotherapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x